Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release topline data by the end of the year. The CEO, Thomas Feldthus, see this as a milestone and a crucial step towards the goal of starting a clinical proof-of-concept study in children with absence seizures next year.
- This study with SAN711 in healthy volunteers offers valuable insights into the appropriate dosing for our phase II trial, helping to ensure positive outcomes.